GleamWall
中文EN

RLAY Relay Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1812364 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY23.9%
TTM net income YoY1.3%
TTM EPS YoY12.8%
Revenue 3-yr CAGR-26.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-3,094.6%
Net margin-2,837.0%
FCF margin—
EBITDA margin-3,077.7%

Returns

ROE-41.2%
ROA-37.4%
ROIC (approx.)-41.8%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets9.2%
Debt / equity0.00x
Current ratio14.62x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-10.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$15.36M$10.01M
R&D expense$261.38M$319.09M
SG&A expense$56.71M$76.59M
Operating income-$302.74M-$372.47M
Income tax$0$0
Net income-$276.48M-$337.71M
EBITDA-$299.18M-$367.00M
EPS (basic)-1.61-2.36
EPS (diluted)-1.61-2.36
Balance sheet
Cash & equivalents$84.02M$126.41M
Current assets$578.28M$809.20M
PP&E, net$1.73M$5.91M
Total assets$621.33M$871.30M
Current liabilities$25.58M$50.73M
Total liabilities$54.27M$93.50M
Shareholders' equity$567.06M$777.79M
Shares outstanding173.87M167.76M
Cash flow statement
Operating cash flow-$235.46M-$249.11M
Capital expenditure$410,000$2.02M
Free cash flow-$235.87M-$251.12M
Investing cash flow$192.80M-$41.08M
Financing cash flow$1.60M$270.15M
Depreciation & amortization$3.56M$5.46M
Stock-based compensation$62.42M$94.14M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.